Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...
Baird analyst Catherine Schulte maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and raises the price target from $7...
Benchmark analyst Bruce D. Jackson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $60 to...
Guggenheim analyst Subbu Nambi maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $70 to $75.
Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and raises the price target from $65 ...
Stifel analyst Daniel Arias maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $67 to $80.
BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $75 to $85.
